Biosimilars Insulin Market Report

Global Biosimilars Insulin Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 25, 2022
  • PAGES：173
  • REPORT CODE：GMM777998
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Biosimilars Insulin market report explains the definition, types, applications, major countries, and major players of the Biosimilars Insulin market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Mylan

    • Merck

    • Boehringer Ingelheim

    • Pfizer

    • Eli Lilly

    • Biocon

    By Type:

    • Insulin Glargine Basaglar

    • Insulin Lantus

    By End-User:

    • Type I Diabetes

    • Type II Diabetes

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Biosimilars Insulin Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Biosimilars Insulin Outlook to 2028- Original Forecasts

    • 2.2 Biosimilars Insulin Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Biosimilars Insulin Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Biosimilars Insulin Market- Recent Developments

    • 6.1 Biosimilars Insulin Market News and Developments

    • 6.2 Biosimilars Insulin Market Deals Landscape

    7 Biosimilars Insulin Raw Materials and Cost Structure Analysis

    • 7.1 Biosimilars Insulin Key Raw Materials

    • 7.2 Biosimilars Insulin Price Trend of Key Raw Materials

    • 7.3 Biosimilars Insulin Key Suppliers of Raw Materials

    • 7.4 Biosimilars Insulin Market Concentration Rate of Raw Materials

    • 7.5 Biosimilars Insulin Cost Structure Analysis

      • 7.5.1 Biosimilars Insulin Raw Materials Analysis

      • 7.5.2 Biosimilars Insulin Labor Cost Analysis

      • 7.5.3 Biosimilars Insulin Manufacturing Expenses Analysis

    8 Global Biosimilars Insulin Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Biosimilars Insulin Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Biosimilars Insulin Export by Region (Top 10 Countries) (2017-2028)

    9 Global Biosimilars Insulin Market Outlook by Types and Applications to 2022

    • 9.1 Global Biosimilars Insulin Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Insulin Glargine Basaglar Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Insulin Lantus Consumption and Growth Rate (2017-2022)

    • 9.2 Global Biosimilars Insulin Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Type I Diabetes Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Type II Diabetes Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Biosimilars Insulin Market Analysis and Outlook till 2022

    • 10.1 Global Biosimilars Insulin Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Biosimilars Insulin Consumption (2017-2022)

      • 10.2.2 Canada Biosimilars Insulin Consumption (2017-2022)

      • 10.2.3 Mexico Biosimilars Insulin Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Biosimilars Insulin Consumption (2017-2022)

      • 10.3.2 UK Biosimilars Insulin Consumption (2017-2022)

      • 10.3.3 Spain Biosimilars Insulin Consumption (2017-2022)

      • 10.3.4 Belgium Biosimilars Insulin Consumption (2017-2022)

      • 10.3.5 France Biosimilars Insulin Consumption (2017-2022)

      • 10.3.6 Italy Biosimilars Insulin Consumption (2017-2022)

      • 10.3.7 Denmark Biosimilars Insulin Consumption (2017-2022)

      • 10.3.8 Finland Biosimilars Insulin Consumption (2017-2022)

      • 10.3.9 Norway Biosimilars Insulin Consumption (2017-2022)

      • 10.3.10 Sweden Biosimilars Insulin Consumption (2017-2022)

      • 10.3.11 Poland Biosimilars Insulin Consumption (2017-2022)

      • 10.3.12 Russia Biosimilars Insulin Consumption (2017-2022)

      • 10.3.13 Turkey Biosimilars Insulin Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Biosimilars Insulin Consumption (2017-2022)

      • 10.4.2 Japan Biosimilars Insulin Consumption (2017-2022)

      • 10.4.3 India Biosimilars Insulin Consumption (2017-2022)

      • 10.4.4 South Korea Biosimilars Insulin Consumption (2017-2022)

      • 10.4.5 Pakistan Biosimilars Insulin Consumption (2017-2022)

      • 10.4.6 Bangladesh Biosimilars Insulin Consumption (2017-2022)

      • 10.4.7 Indonesia Biosimilars Insulin Consumption (2017-2022)

      • 10.4.8 Thailand Biosimilars Insulin Consumption (2017-2022)

      • 10.4.9 Singapore Biosimilars Insulin Consumption (2017-2022)

      • 10.4.10 Malaysia Biosimilars Insulin Consumption (2017-2022)

      • 10.4.11 Philippines Biosimilars Insulin Consumption (2017-2022)

      • 10.4.12 Vietnam Biosimilars Insulin Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Biosimilars Insulin Consumption (2017-2022)

      • 10.5.2 Colombia Biosimilars Insulin Consumption (2017-2022)

      • 10.5.3 Chile Biosimilars Insulin Consumption (2017-2022)

      • 10.5.4 Argentina Biosimilars Insulin Consumption (2017-2022)

      • 10.5.5 Venezuela Biosimilars Insulin Consumption (2017-2022)

      • 10.5.6 Peru Biosimilars Insulin Consumption (2017-2022)

      • 10.5.7 Puerto Rico Biosimilars Insulin Consumption (2017-2022)

      • 10.5.8 Ecuador Biosimilars Insulin Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Biosimilars Insulin Consumption (2017-2022)

      • 10.6.2 Kuwait Biosimilars Insulin Consumption (2017-2022)

      • 10.6.3 Oman Biosimilars Insulin Consumption (2017-2022)

      • 10.6.4 Qatar Biosimilars Insulin Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Biosimilars Insulin Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Biosimilars Insulin Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Biosimilars Insulin Consumption (2017-2022)

      • 10.7.2 South Africa Biosimilars Insulin Consumption (2017-2022)

      • 10.7.3 Egypt Biosimilars Insulin Consumption (2017-2022)

      • 10.7.4 Algeria Biosimilars Insulin Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Biosimilars Insulin Consumption (2017-2022)

      • 10.8.2 New Zealand Biosimilars Insulin Consumption (2017-2022)

    11 Global Biosimilars Insulin Competitive Analysis

    • 11.1 Mylan

      • 11.1.1 Mylan Company Details

      • 11.1.2 Mylan Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Mylan Biosimilars Insulin Main Business and Markets Served

      • 11.1.4 Mylan Biosimilars Insulin Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Merck

      • 11.2.1 Merck Company Details

      • 11.2.2 Merck Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Merck Biosimilars Insulin Main Business and Markets Served

      • 11.2.4 Merck Biosimilars Insulin Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Boehringer Ingelheim

      • 11.3.1 Boehringer Ingelheim Company Details

      • 11.3.2 Boehringer Ingelheim Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Boehringer Ingelheim Biosimilars Insulin Main Business and Markets Served

      • 11.3.4 Boehringer Ingelheim Biosimilars Insulin Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Pfizer

      • 11.4.1 Pfizer Company Details

      • 11.4.2 Pfizer Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Pfizer Biosimilars Insulin Main Business and Markets Served

      • 11.4.4 Pfizer Biosimilars Insulin Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Eli Lilly

      • 11.5.1 Eli Lilly Company Details

      • 11.5.2 Eli Lilly Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Eli Lilly Biosimilars Insulin Main Business and Markets Served

      • 11.5.4 Eli Lilly Biosimilars Insulin Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Biocon

      • 11.6.1 Biocon Company Details

      • 11.6.2 Biocon Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Biocon Biosimilars Insulin Main Business and Markets Served

      • 11.6.4 Biocon Biosimilars Insulin Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    12 Global Biosimilars Insulin Market Outlook by Types and Applications to 2028

    • 12.1 Global Biosimilars Insulin Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Insulin Glargine Basaglar Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Insulin Lantus Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Biosimilars Insulin Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Type I Diabetes Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Type II Diabetes Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Biosimilars Insulin Market Analysis and Outlook to 2028

    • 13.1 Global Biosimilars Insulin Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.2.2 Canada Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Biosimilars Insulin Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.2 UK Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.3 Spain Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.5 France Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.6 Italy Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.8 Finland Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.9 Norway Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.11 Poland Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.12 Russia Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Biosimilars Insulin Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.2 Japan Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.3 India Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Biosimilars Insulin Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.5.3 Chile Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.5.6 Peru Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Biosimilars Insulin Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.6.3 Oman Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Biosimilars Insulin Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Biosimilars Insulin Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Biosimilars Insulin Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Biosimilars Insulin Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Biosimilars Insulin

    • Figure of Biosimilars Insulin Picture

    • Table Global Biosimilars Insulin Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Biosimilars Insulin Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Insulin Glargine Basaglar Consumption and Growth Rate (2017-2022)

    • Figure Global Insulin Lantus Consumption and Growth Rate (2017-2022)

    • Figure Global Type I Diabetes Consumption and Growth Rate (2017-2022)

    • Figure Global Type II Diabetes Consumption and Growth Rate (2017-2022)

    • Figure Global Biosimilars Insulin Consumption by Country (2017-2022)

    • Table North America Biosimilars Insulin Consumption by Country (2017-2022)

    • Figure United States Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Canada Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Mexico Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Table Europe Biosimilars Insulin Consumption by Country (2017-2022)

    • Figure Germany Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure UK Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Spain Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Belgium Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure France Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Italy Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Denmark Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Finland Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Norway Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Sweden Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Poland Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Russia Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Turkey Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Table APAC Biosimilars Insulin Consumption by Country (2017-2022)

    • Figure China Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Japan Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure India Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure South Korea Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Thailand Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Singapore Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Philippines Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Table South America Biosimilars Insulin Consumption by Country (2017-2022)

    • Figure Brazil Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Colombia Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Chile Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Argentina Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Peru Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Table GCC Biosimilars Insulin Consumption by Country (2017-2022)

    • Figure Bahrain Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Oman Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Qatar Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Table Africa Biosimilars Insulin Consumption by Country (2017-2022)

    • Figure Nigeria Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure South Africa Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Egypt Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure Algeria Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Table Oceania Biosimilars Insulin Consumption by Country (2017-2022)

    • Figure Australia Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Biosimilars Insulin Consumption and Growth Rate (2017-2022)

    • Table Mylan Company Details

    • Table Mylan Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Biosimilars Insulin Main Business and Markets Served

    • Table Mylan Biosimilars Insulin Product Portfolio

    • Table Merck Company Details

    • Table Merck Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Biosimilars Insulin Main Business and Markets Served

    • Table Merck Biosimilars Insulin Product Portfolio

    • Table Boehringer Ingelheim Company Details

    • Table Boehringer Ingelheim Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Biosimilars Insulin Main Business and Markets Served

    • Table Boehringer Ingelheim Biosimilars Insulin Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Biosimilars Insulin Main Business and Markets Served

    • Table Pfizer Biosimilars Insulin Product Portfolio

    • Table Eli Lilly Company Details

    • Table Eli Lilly Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Biosimilars Insulin Main Business and Markets Served

    • Table Eli Lilly Biosimilars Insulin Product Portfolio

    • Table Biocon Company Details

    • Table Biocon Biosimilars Insulin Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Biosimilars Insulin Main Business and Markets Served

    • Table Biocon Biosimilars Insulin Product Portfolio

    • Figure Global Insulin Glargine Basaglar Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Insulin Lantus Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Type I Diabetes Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Type II Diabetes Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Biosimilars Insulin Consumption Forecast by Country (2022-2028)

    • Table North America Biosimilars Insulin Consumption Forecast by Country (2022-2028)

    • Figure United States Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Biosimilars Insulin Consumption Forecast by Country (2022-2028)

    • Figure Germany Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Biosimilars Insulin Consumption Forecast by Country (2022-2028)

    • Figure China Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Biosimilars Insulin Consumption Forecast by Country (2022-2028)

    • Figure Brazil Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Biosimilars Insulin Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Biosimilars Insulin Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Biosimilars Insulin Consumption Forecast by Country (2022-2028)

    • Figure Australia Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Biosimilars Insulin Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US